News
TRVI
2.835
+5.59%
0.150
Weekly Report: what happened at TRVI last week (0408-0412)?
Weekly Report · 5d ago
Analysts Anticipate IWN To Hit $180
NASDAQ · 04/10 14:54
Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
Data from the Phase 2 CANAL trial will be presented at the American Thoracic Society 2024 International Conference in San Diego. Trevi Therapeutics is developing Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough.
Benzinga · 04/09 11:32
Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham
Dow Jones · 04/09 10:16
Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target
Benzinga · 04/09 10:06
Understanding Analyst Recommendation Reports: A Guide to Effective Summaries
TipRanks · 04/09 10:05
Weekly Report: what happened at TRVI last week (0401-0405)?
Weekly Report · 04/08 10:57
Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick
NASDAQ · 04/04 12:30
CALM,PLAY and VNDA are among after hour movers
On the Move CALM, PLAY and VNDA are among after hour movers. Sight Sciences (SGHT) and Cal-Maine Foods (CALM) gain. Acorda Therapeutics (ACOR) and Dave & Buster's Entertainment (PLAY) are losers.
Seeking Alpha · 04/02 20:43
Press Release: Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team. Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications. Dr. Garin joins Trevi with over 14 years of industry and academic research experience. Trevi is developing the investigational therapy haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis.
Dow Jones · 04/02 11:30
Weekly Report: what happened at TRVI last week (0325-0329)?
Weekly Report · 04/01 10:55
Weekly Report: what happened at TRVI last week (0318-0322)?
Weekly Report · 03/25 10:57
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Oculis Holding (OCS) and Quanterix (QTRX)
Trevi Therapeutics, Oculis Holding and Quanterix have 3 analysts with bullish sentiments on the Healthcare sector. Trevi has a Buy rating from Leerink Partners and is expected to make a move soon. The 3 stocks are most likely to make moves following their insider activities.
TipRanks · 03/25 01:30
Buy Rating for Trevi Therapeutics Anchored on Haduvio’s Clinical Promise and Market Potential
TipRanks · 03/22 12:05
Trevi Therapeutics Price Target Maintained With a $9.00/Share by Oppenheimer
Dow Jones · 03/21 13:02
Trevi Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 03/21 13:02
Oppenheimer Maintains Outperform on Trevi Therapeutics, Maintains $9 Price Target
Benzinga · 03/21 12:56
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vor Biopharma (VOR), Roche Holding AG (OtherRHHVF) and Trevi Therapeutics (TRVI)
TipRanks · 03/21 11:50
Trevi Therapeutics (TRVI) Receives a Buy from Stifel Nicolaus
TipRanks · 03/21 11:27
Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham
Dow Jones · 03/21 11:03
More
Webull provides a variety of real-time TRVI stock news. You can receive the latest news about Trevi Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.